Table 1.
Patient characteristics
| Characteristics | Value |
|---|---|
| Median age (range), y | 57.5 (41-79) |
| Median number of previous lines of treatment (range) | 3 (2-8) |
| Previous ASCT, n (%) | 46 (95.83) |
| >1 ASCT, n (%) | 10 (20.83) |
| Disease characteristics | |
| High-risk cytogenetics∗, n (%) | 16 (33.33) |
| Extramedullary disease, n (%) | 14 (29.17) |
| Number of focal lesions, n (%) | |
| None | 4 (8.33) |
| 1-3 | 14 (29.17) |
| 4-10 | 6 (12.50) |
| >10 | 24 (50.00) |
| Number of lytic lesions, n (%) | |
| None | 5 (10.42) |
| 1-3 | 8 (16.67) |
| 4-10 | 13 (27.08) |
| >10 | 22 (45.83) |
| Triple-drug refractory, n (%) | 38 (79.17) |
| Penta-drug refractory, n (%) | 15 (31.25) |
| Product infused | |
| Ide-Cel, n (%) | 37 (77.08) |
| Ciltacabtagene autoleucel, n (%) | 5 (10.42) |
| ARI0002h, n (%) | 3 (6.25) |
| Other, n (%) | 3 (6.25) |
| Baseline blood count | |
| Median hemoglobin, g/dL (range) | 11.2 (7.9-14.5) |
| Median platelet count per μL (range) | 139 500 (34 000-387 000) |
| Median ANC per μL (range) | 2355 (2010-285) |
| Hemoglobin <8 g/dL, n (%) | 1 (2.08) |
| Platelets <50 000/μL, n (%) | 2 (4.17) |
| ANC <1000 cells per μL, n (%) | 3 (6.25) |
| Median markers of inflammation at baseline | |
| Lactate dehydrogenase, U/L (range) | 237 (213-275) |
| Ferritin, ng/mL (range) | 368 (279-642.8) |
| D dimer, U/L (range) | 605 (410-740) |
| Fibrinogen, mg/dL (range) | 432 (364-506) |
| HEMATOTOX score | |
| Low (0 or 1 point), n (%) | 29 (60.42) |
| 0 points | 12 |
| 1 point | 17 |
| High (≥2 points), n (%) | 19 (39.58) |
| 2 points | 9 |
| 3 points | 5 |
| 4 points | 1 |
| 5 points | 3 |
| 6 points | 0 |
| 7 points | 1 |
Patient baseline characteristics before CAR-T infusion.
ANC, absolute neutrophil count; ASCT, autologous stem cell transplantation; IMiD, immunomodulatory drug; PI, proteasome inhibitor.
∗
High-risk cytogenetics include t(4;14), t(14;16), t(14;20), and/or del(17p). Triple-drug refractory disease indicates refractory to an IMiD, PI, and daratumumab; penta-drug refractory indicates refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab.